BIIB ▼ -0.8% - Biogen Inc. $BIIB - Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus 02-OCT-2026 11:20 AM ET